Nonpeptide arginine vasopressin antagonists for both V(1A) and V2 receptors: Synthesis and pharmacological properties of 4'-(1,4,5,6- tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d] [1]benzoazepine-6-carbonyl)benzanilide derivatives

Chemical and Pharmaceutical Bulletin

Volumn 48, Issue 1, 2000, Pages 21-31

  Matsuhisa, Akira ^a   Taniguchi, Nobuaki ^a   Koshio, Hiroyuki ^a   Yatsu, Takeyuki ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antidiuretic hormone; Arginine vasopressin antagonist; Benzoazepine; Congestive heart failure; Conivaptan hydrochloride; YM087

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 4' (5,6 DIHYDRO 4H THIAZOLO[5,4D][1]BENZOAZEPINE 6 CARBONYL)BENZANILIDE; ARGIPRESSIN DERIVATIVE; CONIVAPTAN; MOZAVAPTAN; OXYTOCIN RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EDEMA; HYPERTENSION; HYPONATREMIA; KIDNEY; KIDNEY DISEASE; LIVER MEMBRANE; NONHUMAN; RABBIT; RAT; UTERUS;

EID: 0033956395     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.48.21     Document Type: Article

References (24)

1. Michel R. H., Kirk C. J., Billah M. M., Biochem. Soc. Trans., 7, 861-865 (1979).
2. Jard S., Kidney Int., Supp., 26, 38-42 (1988).
3. Yatsu T., Tomura Y., Tahara A., Wada K., Tsukada J., Uchida W., Tanaka A., Takenaka T., Eur. J. Pharmacol., 321, 225-230 (1997).
4. Manning M., Sawyer W. H., J. Lab. Clin. Med., 114, 617-632 (1989).
5. Creager M. A., Facon D. P., Cutler S. S., Kohlmann O., Ryan T. J., Gavras H., J. Am. Coll. Cardiol., 7, 758-765 (1986).
6. Goldsmith S. R., Francis G. S., Cowly A. W. Jr., Goldenberg I. F., Cohn J. N., J. Am. Coll. Cardiol., 8, 779-783 (1986).
7. Lee W. H., Packer M., Circulation, 73, 257-267 (1986).
8. Mulinari R. A., Gavras I., Wang Y. X., Franco R., Gavras H., Circulation, 81, 308-311 (1990).
9. Naitoh M., Suzuki H., Murakami M., Matsumoto A., Arakawa K., Ichihara A., Nakamoto H., Oka K., Yamamura Y., Saruta T., Am. J. Physiol., 267, H2245-H2254 (1994).
10. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Takanashi M., Yatsu T., Uchida W., Tanaka A., J. Pharmacol. Exp. Ther., 282, 301-308 (1997).
11. Matsuhisa A., Koshio H., Sakamoto K., Taniguchi N., Yatsu T., Tanaka A., Chem. Pharm. Bull., 47, 329-339 (1999).
12. th ACS National Meeting, Division of Medicinal Chemistry 140, New Orleans, March, 1996.
13. Commercially unavailable thioamide, thiourea and amidine were synthesized according to the literature described below. a) Walter W., Voss J., "The Chemistry of Amides," Chapter. 8, ed. by Zabicky J., Interscience Publishers, London, 1970, pp. 415-432;
14. b) Shabana R., Mayer H. J., Lawesson S.-O., Phosphorous and Sulfur, 25, 297-305 (1985);
15. c) Sandler S. R., Karo W., "Organic Functional Group Preparations,"Vol. 2, Chapter. 6, ed. by Blomquist A. T., Academic Press, New York, 1971, pp. 134-165;
16. d) Sandler S. R., Karo W., "Organic Functional Group Preparations,"Vol. 3, Chapter. 6, eds. by Blomquist A. T., Wasserman H., Academic Press, New York, 1972, pp. 205-
17. 240;
18. e) Gautier J.-A., Miocque M., Farnoux C. C., "The Chemistry of Amidines and Imidates," Chapter. 7, ed. by Patai S., Wiley & Sons, London, 1975, pp. 285-312.
19. Ogawa H., Yamashita H., Kondo K., Yamamura Y., Miyamoto H., Kan K., Kitano K., Tanaka M., Nakaya K., Nakamura S., Mori T., Tominaga M., Yabuuchi Y., J. Med. Chem., 39, 3547-3555 (1996).
20. 2 receptor binding affinity potential of some compounds for rat kidney and for rabbit kidney in our investigation (data not shown).
21. Matsuhisa A., Koshio H., Sakamoto K., Taniguchi N., Yatsu T., Tanaka A., Chem. Pharm. Bull., 46, 1566-1579 (1998).
22. c log P values were calculated with CLOGP (Tripos, Inc). c log P values of some test compounds: 11, 5.79; 15, 5.62; 17c, 4.90; 18, 4.75; 19, 5.28; 20, 5.81; 31a, 3.52; 31b, 4.15; 31c, 3.47; 31d, 4.00; 31e, 4.31; 31f, 3.22; 31g, 5.25.
23. Tahara A., Saito M., Sugimoto T., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A., Naunyn-Schmiedeberg's Arch. Pharmacol., 357, 63-69 (1998).
24. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A., Peptides, 19, 691-696 (1998).